We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SomaGenics Secures NIH Funding
News

SomaGenics Secures NIH Funding

SomaGenics Secures NIH Funding
News

SomaGenics Secures NIH Funding

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SomaGenics Secures NIH Funding"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SomaGenics has been awarded a $1.8M two-year NIH SBIR Phase II grant to further develop its RealSeq–AC technology for next-generation sequencing (NGS) of small RNAs such as microRNA.

Real-Seq®-AC dramatically reduces bias in small RNA sequencing libraries compared to commercially available library construction methods.  “Bias reduction is critical for the discovery of previously undetected RNAs and enables a more accurate analysis of small RNA abundances,” according to Dr. Sergei Kazakov, VP of Discovery Research at SomaGenics and Principal Investigator on the NIH grant.   

This Phase II award allows SomaGenics to further develop the RealSeq-AC library construction approach including streamlining the workflow, increasing library yield, and broadening its utility beyond sequencing microRNAs to include other RNA species such tRNAs, fragments of mRNAs and long noncoding RNAs (lncRNAs).

“This additional funding will allow us to continue expanding and optimizing the RealSeq platform, further strengthening SomaGenics’ suite of tools for small RNA discovery and validation.  Besides RealSeq, these tools also include our proprietary RT-qPCR technologies miR-ID and miR-Direct, which can be used to validate potential biomarkers discovered through sequencing”, commented Dr. Brian Johnston, CEO of SomaGenics.

Advertisement